Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant ganglioside GM2-KLH/QS-21 vaccination: post-operative adjuvant ganglioside GM2-KLH/QS-21 (BMS-248479) vaccination treatment after resection of primary cutaneous melanoma thicker than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-arm multicenter randomized phase III trial vs. observation.

Next Previous
X
Search
Trial Profile

Adjuvant ganglioside GM2-KLH/QS-21 vaccination: post-operative adjuvant ganglioside GM2-KLH/QS-21 (BMS-248479) vaccination treatment after resection of primary cutaneous melanoma thicker than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-arm multicenter randomized phase III trial vs. observation.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melanoma vaccine (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 07 Jun 2016 Results assessing IgG serum antibody responses of stage II melanoma patients of the EORTC 18961 trial presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 09 Dec 2015 Accrual till date is 32% according to United Kingdom Clinical Research Network record.
    • 09 Sep 2013 Results published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top